Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Colorectal Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Colorectal Cancer. According to...
Adebrelimab by Jiangsu Hengrui Medicine for Cervical Cancer: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Cervical Cancer. According to GlobalData,...
Famitinib by Jiangsu Hengrui Medicine for Cervical Cancer: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Cervical Cancer. According to GlobalData,...
Famitinib by Jiangsu Hengrui Medicine for Anaplastic Thyroid Cancer: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Anaplastic Thyroid Cancer. According to...
Famitinib by Jiangsu Hengrui Medicine for Thyroid Cancer: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Thyroid Cancer. According to GlobalData,...
Famitinib by Jiangsu Hengrui Medicine for Medullary Thyroid Cancer: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Medullary Thyroid Cancer. According to...
Dalpiciclib by Jiangsu Hengrui Medicine for Nasopharyngeal Cancer: Likelihood of Approval
Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData,...
Fuzuloparib by Jiangsu Hengrui Medicine for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Fuzuloparib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction....
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Ovarian Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Ovarian Cancer. According to...
Camrelizumab by Jiangsu Hengrui Medicine for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...
HRS-5965 by Jiangsu Hengrui Medicine for Lupus Nephritis: Likelihood of Approval
HRS-5965 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Lupus Nephritis. According to GlobalData,...
Adebrelimab by Jiangsu Hengrui Medicine for Advanced Malignancy: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Advanced Malignancy. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Metastatic Melanoma: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Metastatic Melanoma. According to GlobalData,...
Famitinib by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...
SHR-1702 by Jiangsu Hengrui Medicine for Refractory Acute Myeloid Leukemia: Likelihood of Approval
SHR-1702 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Refractory Acute Myeloid Leukemia. According...
SHR-1501 by Jiangsu Hengrui Medicine for Advanced Malignancy: Likelihood of Approval
SHR-1501 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Advanced Malignancy. According to GlobalData,...
Dexmedetomidine hydrochloride 1 by Jiangsu Hengrui Medicine for Pain: Likelihood of Approval
Dexmedetomidine hydrochloride 1 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Pain. According to...
Rafutrombopag by Jiangsu Hengrui Medicine for Thrombocytopenia: Likelihood of Approval
Rafutrombopag is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Thrombocytopenia. According to GlobalData, Phase...
SHR-1702 by Jiangsu Hengrui Medicine for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
SHR-1702 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Relapsed Acute Myeloid Leukemia. According...
SHR-1702 by Jiangsu Hengrui Medicine for Myelodysplastic Syndrome: Likelihood of Approval
SHR-1702 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData,...